Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes, look down to the second weekly chart to see that perfectly rounded cup with heavy buying on its right side and it seems to be forming a downwardly sloping handle on low volume in the top half of the cup -textbook! The markets extreme volatility of late has made for wider swings on this stock lately.
http://stockcharts.com/charts/gallery.html?cerp
CERP Yahoo Board is the most active board
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_C/forumview?bn=29240
YAHOO MESSAGE BOARD NOW THE MOST ACTIVE NGNM BOARD
http://messages.finance.yahoo.com/mb/NGNM.OB
Yahoo NGNM Message board now open...
http://messages.finance.yahoo.com/mb/NGNM.OB
there was a single 270K print that sent the day's volume total into the 400's...not sure if it was a buy or a sell...overall I'm seeing general accumulation in the chart.
I'm moving on to NGNM google message board.
I think with Neogenomics' increasing awareness the google board should become more active than this one. Whenever NGNM moves off the over-the-counter penny stock listings the Yahoo board should open up -but I dislike the yahoo boards- a person has to sort through too much crap to get to the intelligent posts.
Google message board for NGNM:
http://finance.google.com/group/google.finance.12209185/messages
I was thinking maybe just a 10 to 15% drop on the announcement of the share dilution. I don't think it would fall below the 50 day line (currently it's at $1.27). Institutional investors are entering the stock and they tend to support the price by not letting it fall below the 50 day average line. They will prop it up anytime it starts approaching it. That is a common trait of stock that has institutional support. You can see it in NGNM's chart this year. http://stockcharts.com/gallery/?NGNM So a warning sign would be if the price plummeted through that line on high volume -meaning the institutional investors were exiting the stock and no longer supporting it.
Based on Gasparini's track record and the area that this company does business in...I could see the stock doubling to $4 next year then doubling again to $8 and so on...but when we enter a bear market or a correction -all those gains will be put on hold or even given back. If NGNM starts to fall in sync with the market then it will probably be a good time to take profits and sit on the sidelines till the correction is over (3 out of 4 stocks follow the market's general direction) BUT if NGNM were to hold its stock price or only fall a little bit that would mean it is a very strong stock and should be held since it would then skyrocket out of the gate when the next bull market started.
Pullbacks on declining volume is what I like to see...just like the last two days.
At the JPM conference, management said they would be raising additional funds in 1H07...$2 to 3M...which could go for paying off the $1.5M debt. That will bring more dilution to the share count and a sell off on the announcement but that will be a good time to add shares as I expect the share price to quickly recover. This rocket ride will then be debt free and even more attractive to investors. I would think the JPM investors wouldn't want to wait till next year to buy in so maybe we will see that financing happening sooner than planned and for a larger amount.
I was looking at the long term chart for PTRY -a convenience store chain. It went from $1 to $70 in 4 years. I wonder if this stock could do the same? Especially now that they announced they will be doing research and development and will be looking to introduce intellectual property into their business model.
Excellent Rapid-Rapid pace presentation!
I think Robert took only two breaths during the first 15 minutes! Lots of specific details about the business and future potential. This is definitely a rocket ride!
Hit a high of $2.05 today! And it continually keeps rising on -heavy- above average volume. A warning sign would be if it were to be hitting new highs on below average volume. That ain't happening here.
http://www.mapdigital.com/jpmorgan/smallcapboston06/
once you register, they are under on-demand web casts. Lots of important information for NGNM investors...
Another strategy note from IBD:
Pullbacks To 10-Week Line Offer 2nd Chance
Some stocks give you a second chance.
Maybe you were slow in pulling the trigger and missed buying into a stock as it broke out of its base. Or perhaps you were quick enough to snatch up some shares, but want to add to your holdings.
Winning stocks will periodically take a break during their run and drift back to their 10-week or 50-day moving averages. A stock that bounces off these key benchmarks is said to be finding institutional support. That means big investors are stepping in to buy shares and, by boosting demand, lifting the price.
The easiest way to determine when to buy shares is to look at a weekly stock chart. Mini charts in Investor's Business Daily and weekly charts at investors.com show the 10-week and 40-week average lines.
When a growth stock that's been heading higher falls back to touch its 10-week or 50-day line, then begins to climb higher, it's time to start scouting out a buy point.
The buy point is 0.10 above the highest price the stock hit before it began to pull back.
Ideally, you like to see volume pick up as a stock ricochets off its moving average line - the bigger the volume, the more institutional support it's attracting.
On the flip side, a stock that falls through its 10-week moving average on heavy volume and continues south may be in trouble. If you own it, you might consider selling, especially if the stock cannot rally back.
OT: I sure like the spell checker that google has on their free web browser toolbar...comes in real handy for spell checking these comments before posting here and on the yahoo boards.
http://toolbar.google.com/T4/index_xp.html?utm_source=en-et-more&utm_medium=et&utm_campaign=...
Keep in mind that the main purpose of a companies attendance at these conferences, such as the JP Morgan Small Cap Conference, is to raise additional funding and investment. Usually a PR will follow these events announcing the sale of more shares...the stock will fall on that news but it can be a good time to add shares since the price will typically recover in a month or two. Neogenomics is going to need additional cash to fund the new lab in Southern California. I also expect them to acquire additional companies in other areas of the country, since as they said they are in acquisition mode.
NeoGenomics enjoys $1.6M revenue growth
NeoGenomics has added employees, tripling its staff in Nashville and doubling the size of its sales team.
By Laura Layden
Saturday, November 11, 2006
It's all in the genes.
Fort Myers-based NeoGenomics Inc. is growing along with its industry.
The genetic testing company saw revenues climb to more than $1.6 million in the third quarter, a 186 percent increase from the same quarter a year ago.
Profits grew by $271,800 to $32,000, from a loss of $239,900 a year ago.
"This was quite the exciting quarter for us here at NeoGenomics," said Robert Gasparini, the company's president and chief scientific officer, in a conference call Friday.
He said the most significant accomplishment during the quarter was the development of physical and human resources needed to "begin to scale" the company. NeoGenomics has completed an expansion of its Fort Myers headquarters and the build-out of a new 5,400-square-foot laboratory in Nashville, Tenn.
In July, NeoGenomics opened a new laboratory in California, giving it a "bicoastal presence," company officials said.
At the same time, the company has added employees, tripling its staff in Nashville and doubling the size of its sales team.
New hires include Matthew Moore, who has a doctorate in molecular biology and is expected to expand the company's intellectual property and its reach to pharmaceutical research and development organizations. In the past, the company has primarily performed diagnostic testing for patients, not for research.
Also joining NeoGenomics as associate medical director is Frank Yang, a noted hematopathologist.
Steven Jones, acting principle financial officer, said the company's accomplishments in the third quarter are a testament to the strength of its business model.
In the quarter, the company saw a 160 percent increase in the number of tests performed, and a 10 percent increase in the average revenue per test.
Year-over-year the company's profits are up 242 percent. Revenues are up 316 percent.
Based on the growth NeoGenomics has seen so far this year, company officials on Friday raised guidance for 2007. Revenues are now pegged at $14 million to $16 million and profits are estimated at $1.3 million to $1.7 million. The new estimates are based on internal growth, not on acquisitions or new strategic alliances.
The company has been asked to make a presentation to investors at the JP Morgan Small Cap Conference on Wednesday at the Four Seasons Hotel in Boston. Company officials said it was a great honor to be invited. In the past, the company has attracted individual and high net worth investors. Now institutional investors are taking notice.
"We're excited to begin to tell our story," Jones said.
The company reached the milestone of monthly profitability in February. It provides testing services to oncologists, pathologists, urologists, hospitals, and other laboratories. It specializes in genetic testing for cancer.
The company trades under the symbol NGNM on the Over-the-Counter Bulletin Board. Shares closed at $1.59, down 9 cents, on Friday.
© 2006 Naples Daily News and NDN Productions. Published in Naples, Florida, USA by the E.W. Scripps Co.
http://www.naplesnews.com/news/2006/nov/11/neogenomics_enjoys_16m_revenue_growth/?print=1
IBD's investor's corner has this lesson and advice this weekend.
Don't Fall In Love With A Stock — Use Sell Rules To Guide Your Hand
http://www.investors.com/editorial/editorialcontent.asp?secid=1100&status=article&id=2480521...
I check investor's corner everyday -good examples of what to watch out for.
Exciting conference call...lots of good news...being invited to the JP Morgan Small Cap Conference next Wednesday is impressive -Neogenomics will be the smallest cap stock there...obviously, wall street sees the potential of this company. I expect some large institutional investors to enter the stock after next week's conference. They aren't going to pay top price for their shares, though -expect more shakeouts.
Once a stock reaches or goes above the upper bollinger band you can expect a quick trip downward. Plus, like I pointed out it was too high above the 50 day line and ready for a reversal. Or, I wonder if the MM's just wanted to scare and grab the shares of all those who follow those penny stock sheets and took a position on Wed?
Not sure what's next for the stock -depends on what is said tomorrow.
As for the future...people are going to start taking their Q4 profits next month. And I see that large cap stocks are gaining favor which usually happens at the end of a bull market...so we could be heading into a correction or bear market next year which will pull down on this stock...for now, gotta just keeping watching out for warning and sell signs. Today (Thursday) looked like one but the stock ended up reversing and finishing in the upper half of the candlestick -a bullish sign!
see chart: http://stockcharts.com/gallery/?NGNM
I checked the news services and I see OTCpicks.com, twintraders.com, wallstreetnewsalert.com, stockwire.com -all putting alerts out to their penny investors on NGNM. So much for thinking no one knew about this stock -yet. (That's where the volume is coming from.) I'd rather not see these type of companies pumping NGNM. I want to see long term investors in Neogenomics -not penney investors who sell every time the stock goes up 3 cents. Unfortunately, the stock will become very volatile now.
The price is getting way to high above the 50 day line -going to be time for a reversal. Also, keep an eye out for "churning" on Friday. That's when there is extremely heavy volume but the stock price doesn't rise much -too many people selling into the news.
http://stockcharts.com/gallery/?NGNM
NeoGenomics Announces Third Quarter Earnings and Conference Call
FT. MYERS, Fla., Nov. 7 /PRNewswire-FirstCall/ -- NeoGenomics, Inc. (OTC Bulletin Board: NGNM - News) will release its third quarter earnings on Friday, Nov. 10 at 7 a.m.
NeoGenomics will hold a conference call with President and Chief Scientific Officer Robert Gasparini and key members of the management team the same day at 10 a.m. Eastern Time. The call will cover the company's third quarter results and will include a question-and-answer session.
To participate, call (877) 407-8035 any time after 9:50 a.m. Eastern Time on Nov. 10. International and local callers should dial (201) 689-8035. While in conference, if callers should experience any difficulty or require operator assistance, they can press the (*) followed by the (0) button. This will call an operator to the line.
A live webcast of the call will be available at http://www.vcall.com/IC/CEPage.asp?ID=110964 and will be accessible until March 2, 2007. Viewers will need Windows Media Player or Real Player to listen to the broadcast. To download Media Player, go to http://www.microsoft.com/windows/windowsmedia/download.
http://biz.yahoo.com/prnews/061107/clw062.html?.v=68&printer=1
note on monday's activity:
NGNM: Volume Spike; 99% > 20-adsv, Stock +9.33%
Monday , November 06, 2006 16:10ET
This is the 1st VOLUME alert for NGNM in the past 7 calendar days.
Trading for NeoGenomics Inc (OTCBB: NGNM) has been heavier than usual in today's session. By 16:10 ET, the stock had already traded 283,600 shares via 43 trades. The cumulative volume is 98.90% above its 20-day average of 142,582. Normally the stock experiences around 23 individual trades per session.
So far, today's volume surge has caused a net rise in NGNM's stock price. At the time of this alert, the stock was trading at $1.640, up $0.140 (+9.33%).
One year ago, the Company's shares closed at $0.240. The price has gained more than 583 percent since then.
Over the last 10 trading session NGNM has traded in a range between $1.150 and $1.540 and is currently trading 6.49% above its 52-week high of $1.540 set on November 01,2006 and 1266.67% above its 52-week low of $0.120 from January 18,2006.
In the previous 3 sessions, NGNM trading has displayed a mixed trend. Closing results have been as follows:
November 03, 2006 --- closed at $1.500 up $0.040 (+2.74%) on 279,600 shares
November 02, 2006 --- closed at $1.460 down $0.040 (-2.67%) on 63,160 shares
November 01, 2006 --- closed at $1.500 up $0.080 (+5.63%) on 201,000 shares
The Company last released news on September 25, 2006:
"NeoGenomics Unveils Comprehensive Genetic Pathology Solutions (GPS) Product Offering"
NEOGENOMICS INC
NeoGenomics, Inc.'s principle operations include providing cytogenetic and molecular biology diagnostic testing services to the oncology and perinatology sectors of the healthcare industry. The Company also conducts research activities for the early diagnosis of women's diseases, such as ovarian cancer, as well as diseases in prenates and infants.
http://knobias.com/story.htm?eid=3.1.2160c501478e1b0ab77f6e9c9eb265fa6d63b1fdf3b434f7e0e91e0c3b3ea17....
From what I've read, Us Labs is a wholly owned subsidiary of LabCorp now. The parent company, Lab Corp, is LH stock symbol. Look down at the second -weekly chart- and you will see they have done quite well the last 3 years.
http://stockcharts.com/gallery/?lh
NGNM did around 400k today in volume...news is obviously about to hit!
rogerreuss, smart entry and exit on BCON -congrats! You knew that any stock that goes straight up like that -you'd better grab your profits before the sell off. I feel more comfortable this time about NGNM since its rise is happening over a longer period in stages/bases. One still has to watch out for warning/sell signs like a high volume plummet through the 50 day. At some point people will want to take their profit in this stock but I'm guessing it will be a gradual fall not abrupt. Few people know about NGNM yet and we are still in early in this rise yet. Most likely scenario for this company is they will be bought out by Quest Diagnostics (DGX) or Laboratory Corp (LH) at a 50% premium in a couple of years. But then again Gasparini & Jones might not want to sell their baby...
That's good insight on the upcoming $1.75 & $2.00 hurdles. Yes, it usually takes a couple of pull-backs before overtaking future resistance levels.
The rise this year was in part the result of Neogenomics hiring Hawk Associates to promote the stock and provide analyst coverage. NGNM is paying them almost 7K a month for these and investor relation services. I must say though that their analyst, Cale Smith, writes an excellent report and he is even critical at times. Keep in mind though at the moment we have a company that will only net about 500k this year and is 1.5M in debt. But based on Gasparini and his teams past performance and the high-margin market they are in and the 25 to 45% annual growth predicted...we should see a continued escalation of the stock price...just got to be careful that it doesn't get too far out of line but so far we have had high volume to support the rise.
Heavy volume on Friday -280k- and a 53k print after the close. http://tinyurl.com/ye3gzs Average 3 month volume now at 112k. They should’ve announced the Q3 cc by now…what’s up? Probably, very busy.
rogerreuss, to be listed on the Nasdaq small cap stocks, a company needs to have a minimum $4.00 share price amongst other requirements most of I believe NGNM meets. Getting NGNM off the bulletin board penny stocks should be a priority so they can attract the serious big money investors.
And that last company that they helped build in a short amount of time was US Labs (US Pathology Labs) which was bought by Lab Corp (Laboratory Corporation of America) (NYSE: LH) for $155M in 2005. The purchase price was equal to approximately two times US Labs’ annual revenue of about $75 million.
I was reading that Microcap fund manager Michael Corbett was Marketwatch’s Stockpicker of the Quarter. http://tinyurl.com/ydd894 He likes investing in small, unknown stocks. I sent an email to his company…told him to check out Neogenomics :) with a link to the recent small cap conference http://tinyurl.com/yb6a2z
There has been news out...at the Sept 28 conference they said they would be raising guidance...and at the bottom of the GPS Product Offering PR they said they would be revising guidance upward. I'm guessing that they will hold a conference the first week of Nov. so anyday now should come a notice and it will probably say again in it that they will be revising upwards. I have no idea how far the stock will pull-back. Usually volume starts drying up near the bottom then it takes off again. I'm not a technical chartist -I just go by some basic technicals like the 50 & 200 day MA's and bollinger bands and I have a mental list of warning signs I watch out for. But as long as they keep upping their guidance figures the stock will climb.
No crystal ball, just reading the chart and keeping up on the news...let's hope the pull back, when it comes, is not to severe. That was about a 50% run up in just a few days.
3 month average volume at 106k & 50 day ma at $1.04 -lookin' good! I would like to see average volume get up to 200k+...larger buyers will get in once they see more liquidity, starting in that range. Should be a notice out any day now for Q3 conference call.
Sorry, altarboy4, I can't answer that one. I find it hard to guess the price of a stock at any certain time in the future -too many unknown variables come into play. $100 dollar figure seems quite high but anything is possible. I think right now the farthest out people can see is a $4 to $5. dollar price in a couple of years. But if they were to start some research projects soon that could send the stock price even higher.
This company has new management & new products...its revenues are increasing each quarter...it is in a strong growth field...and few people know about it yet...wait till it gets listed on the AMAX or Nasdaq...that would give it another 50 to 100% surge in stock price.
Though, no stock climbs forever...there will be a correction when people start to take profits (stock is up over 1000% from its January low). The stock's climb might also slow after this usual 4th quarter market rally...and we have had a bull market for about 4 years now so it's time for a correction, which will pull down on the stock. At some point I also expect them to draw down on their credit facility and or sell shares to raise money for more acquisitions -another temporary set back for the stock price.
But so far I only see bullish signals in the chart pattern...no sell signs have flashed yet.
Wishin' us continued luck...
Last resistance point for this stock is 52-week high of $1.25...once it moves into new territory it should really start rising fast.
4 weeks of real tight trading...a sign of institutional accumulation...love seeing those flat lines on a chart.... Price is about to run into the 50 day line...I expect a bounce or change upward here shortly. Company has revealed they will be guiding upward again. Analyst Cale Smith's '07 target price was $1.50 to $1.75...lets see what he ups it to after the Q3 conference when Neogenomics announces their revised upward guidance figures. Kaching!
http://stockcharts.com/gallery/?NGNM
Excellent rapid-fire presentation!
I'm impressed with the video and coordinated slide show made available...got to see Robert and Steven up close.
http://hosted.mediasite.com/hosted/viewer/Viewer.aspx?layoutPrefix=LayoutBottomRight&layoutOffse...
NeoGenomics Unveils Comprehensive Genetic Pathology Solutions (GPS) Product Offering
Sep 25 2006, 4:00 AM EST
PRNEWSWIRE
FT. MYERS, Fla., Sept. 25 /PRNewswire-FirstCall/ -- NeoGenomics, Inc. (OTC Bulletin Board: NGNM) a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, unveiled today a new comprehensive testing service targeting the oncology and hematology markets. This new offering called Genetic Pathology Solutions (GPS) combines the results of cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry and morphological testing onto one comprehensive laboratory report.
NeoGenomics President and Chief Scientific Officer Robert Gasparini said, "Our new GPS offering is the right product at the right time focused on the right market. Given the accuracy of genetic testing, more oncology practices are using these services to assist in diagnosing hematological cancers. Recently, the trend has been to order as many as two to four of these genetic tests to confirm diagnoses across testing modalities. Previously, doctors would get these test results at various times due to differing lengths of time required for each test methodology. Because of our superior turn-around-times, we are now able to generate one comprehensive test report for our clients typically within four to five days. This is a huge benefit to doctors who like to review all ancillary testing information at one time in order to make the most comprehensive and accurate diagnosis. Our new GPS product has been warmly received by customers to whom we have rolled it out. Very few other laboratories across the country are set up to provide one comprehensive report to oncology clients, and we believe none are able to do so in time frames equivalent to those of NeoGenomics Laboratories."
NeoGenomics also announced that Dr. Frank Yang, M.D., Ph.D, FCAP, has joined the company as its chief hematopathologist. Before joining NeoGenomics, Dr. Yang worked with Dr. Raul Braylan, a legendary authority in flow cytometric analysis of lymphoma and leukemia at the University of Florida. Yang's work experience includes hematopathologist and clinical assistant professor at the University of Florida, chief hematopathologist at the Milwaukee VA Medical Center and laboratory director of the Tomah VA Medical Center in Wisconsin, and numerous other notable assignments. Dr. Yang is also a former research scientist in the field of molecular biology and medical genetics at the Albert Einstein College of Medicine and University of California at San Francisco. Based on this experience, Dr. Yang understands all aspects of modern hematopathology services.
Gasparini said, "We are honored to have Dr. Yang join our staff. For the last two years, he has worked closely with Dr. Braylan, who is widely considered the father of modern flow cytometry. In addition, Dr. Yang is one of those rare individuals who has achieved not only an M.D. with a specialization in hematopathology, but also a Ph.D. in molecular biology/genetics. His vast experience allows us to bring in-house many new professional services. In particular, we can now provide in-house the professional component of flow cytometry as well as provide morphological and immunohistochemistry testing services. This has allowed NeoGenomics to complete its oncology services bundle, which we believe will make it easier to attract additional oncology customers."
Acting Chief Financial Officer Steven Jones said, "The GPS product allows NeoGenomics to address a much larger segment of the oncology testing market, and we believe it will allow us to increase the average revenue per requisition for our oncology testing services. Indeed, in early trials of this new product offering with oncology practices, we have been able to increase the number of tests ordered per requisition by 25-50%, and our average revenue per requisition for these clients has increased by as much as 60%. As a result of our GPS product offering, we anticipate that our customer mix will continue to evolve. In particular, we have begun to attract additional higher-margin oncology practices, and we are seeing a decline in volume from some of our lower margin reference laboratory customers due to a perception that our new GPS product conflicts with some of their own services. This evolution of our customer mix has been expected and, given the level of interest in the GPS product to date, we expect that any lost revenues from reference lab customers will be more than offset by new higher margin oncology clients in fairly short order. Overall, we are excited about the impact that we believe the GPS product will have on our growth rate in FY 2007. As we announced with our Q2 06 earnings release we plan to issue revised upward guidance for FY 2007 with our Q3 06 earnings release."
About NeoGenomics, Inc.
NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company analyzes chromosomes, genes and DNA for the presence of cancerous disease states through its cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry and molecular genetic testing services. Headquartered in Fort Myers, Fla., NeoGenomics has labs in Nashville, Tenn., and Ft. Myers and services the needs of oncologists, pathologists, urologists, hospitals and other reference laboratories throughout the United States. For additional information about NeoGenomics, visit http://www.neogenomics.org.
An investment profile about NeoGenomics may be found online at http://www.hawkassociates.com/ngnmprofile.aspx. Interested parties can also access an in-depth equity research report, from the American Microcap Institute at http://www.americanmicrocapinstitute.com/ngnm.
An online investor kit including press releases, current price quotes, stock charts and other valuable information for investors may be found at http://www.hawkassociates.com and http://www.americanmicrocaps.com.
http://www.genengnews.com/news/bnitem.aspx?name=6053930
stock holding at $1.00
http://stockcharts.com/gallery/?NGNM
also one of the directors resigned
http://biz.yahoo.com/e/060908/ngnm.ob8-k.html
Neogenomics related news
Congratulations to Tiffany and William
http://www.norwichbulletin.com/apps/pbcs.dll/article?AID=/20060827/LIFESTYLE/608270365/1024/LIFESTYL....
15 vs 3
In checking the weekly chart -weekly is best for seeing a clearer picture of stock performance- one can see that starting with the first turnaround week last January...there have been 15 weeks of above average buying volume versus just 3 weeks of above average selling volume. This is extremely bullish. Hardly anyone knows about this company, yet...just wait till they do!
The weekly chart is the second one down. I like "stockcharts" the best for a free stock chart site. Just click on one of those charts and it will take you back to the main chart where you can adjust various parameters.
http://stockcharts.com/gallery/?NGNM
Heh, Suky, I'm still in this, lettin' my money ride -long term- till that buyout day. I should of sold last year and bought back when it was around 12 cents -but trying to time the market can be difficult...always full of surprises.
Looks like the selling volume is drying up.
You might be thinking of this:
"On January 21, 2006 the Company entered into a subscription agreement (the "Subscription") with SKL Family Limited Partnership, LP, a New Jersey limited partnership, whereby SKL purchased 2.0 million shares (the "Subscription Shares") of the Company's common stock at a purchase price of $0.20/share for $400,000. Under the terms of the Subscription, the Subscription Shares are restricted for a period of 24 months and then carry piggyback registration rights to the extent that exemptions under Rule 144 are not available to SKL. In connection with the Subscription, the Company also issued a five year warrant to purchase 900,000 shares of the Company's common stock at an exercise price of $0.26/share. SKL has no previous affiliation with the Company.
On March 14, 2006, Aspen exercised its Equity Purchase Rights and we issued to Aspen 1,000,000 restricted shares of common stock at a purchase price of $0.20/share for $200,000. In connection with this transaction, the Company also issued a five year warrant to purchase 450,000 shares of common stock at an exercise price of $0.26/share.",
What I don't like -and it appears very suspicious, in my opinion- is the stock got pounded down to 12 cents before that special 20 cent deal for SKL. Someone really was hitting the stock hard taking it down to 12 cents and I couldn't figure out why...everyone knew NGNM was coming out of the red and becoming profitable so why would someone pound the stock down to pennies...I think it's obvious...
Gasparini grew annual revenue in his previous company to 30 million in just 30 months...looks like he is going to do the same again. I would imagine he'll need to get annual revenue up into 100 million and more before we see the kind of share price you envision or if they were to start some research projects that could also accelerate the stock price. Anything is possible, I've learned. This is an exciting stock to be holding.
Gasparini signed a 3 year contract with Neogenomics and if he should not renew for some reason...it would be time to sell.
I agree. These prices seem cheap compared to what it will be in the future. Stock fell to 81 cents today but shot back up. On today's chart it shows up as a bullish hammer pattern. And looking down at the weekly chart you see a large double bottom pattern (looks like a big "W") with the second leg undercutting the first. Very bullish with a lot of positive buying as of late. When this stock breaks that top $1.20's resistance it should really fly...
http://stockcharts.com/gallery/?NGNM
I also see that the $101.10 ask has been removed. Now $6.00 is top asking price.
http://www.americanmicrocaps.com/ngnm/
From Cogent Q2 report:
"We believe that is remarkably cheap for an economically superior business model growing at more than 25% per quarter with enormous potential for expansion for the next five years."
http://www.americanmicrocaps.com/ngnm/NGNM_Q2_Update.pdf
Robert Gasparini makes things happen!
http://www.hawkassociates.com/neogenomics/manage.php
...an excellent 38 page report that Hawk Associates put out on Neogenomics
http://www.amistockreports.com/06_04_03NGNMreport.pdf
I also read that this genetics field is growing at 25% to 30% a year...
Not sure what ran the stock up...didn't see any news. The stock price got too far above the 50 day line and was due to return back down. Volume has steadily been going down, 47k today. Let's see if there isn't another surge since that has been the pattern. I've learned not to predict where a stock price will be since I've been surprised too many times. The 50 day average (based on 3 months of trading) is around 75 cents so the stock should not go lower than that. Like I said the volume has been decreasing during the sell-off so we could be in for another run-up. NGNM's all time high since the reverse split was around $1.22? So that is the resistance we need to pass for the stock to really surge. I noted in an earlier post someone has 100 shares they want to sell at $101.10 (I'd say they made a mistake when entering their bid) but what is funny is if there was a run on the stock and all the asks were taken out, the stock would jump to that figure then back down to normal range. That would be one hell of a spike...that would really bring a lot of attention to the stock. The analyst covering NGNM expects an '06 Target Price: of $0.90-$1.05 and an ‘07 Target Price: $1.50-$1.75. I'm sure he will be continually raising those figures after each quarterly cc.
http://stockcharts.com/gallery/?NGNM
I don't like those sharp spikes. Like the recent spike to $1.25. All you get is a prolonged sell-off for days afterward. Stock was down to 90 cents today (finished at 94 cents)...down down it goes....I wanted to see it hold a dollar...now watching to see if it will bounce off its 50 day.
$101.10?
Must be a mistake. They must of meant to enter $1.01 or $1.10. But the $6.00 ask price is for real.
http://img100.imageshack.us/img100/3623/alistzf1.gif